In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Read the full coverage here: Novel T-cell therapy effective against common viruses after stem cell transplantation FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma Review of meeting abstracts shows toxicity reporting inconsistent, incomplete Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome References: Alexander S, et al. Abstract 901. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans. Chin-Yee B, et al. Abstract 129. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2013; New Orleans. Pfeiffer T, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2415. Press Release Press Release

Ver todos los episodios